The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Breast Cancer Research and Treatment Année : 2009

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

Résumé

The 70-gene signature (MammaPrint™) is a prognostic tool used to guide adjuvant treatment decisions. The aim of this study was to assess its value to predict chemosensitivity in the neoadjuvant setting. We obtained the 70-gene profile of stage II–III patients prior to neoadjuvant chemotherapy and classified the prognosis-signatures. Pathological complete remission (pCR) was used to measure chemosensitivity. Among 167 patients, 144 (86%) were having a poor and 23 (14%) a good prognosis-signature. None of the good prognosis-signature patients achieved a pCR (0/23), whereas 29/144 patients (20%) in the poor prognosis-signature group did ( = 0.015). All triple-negative tumors ( = 38) had a poor prognosis-signature. Within the non triple-negative subgroup, the response of the primary tumor remained associated with the classification of the prognosis-signature ( = 0.023). A pCR is unlikely to be achieved in tumors that have a good prognosis-signature. Tumors with a poor prognosis-signature are more sensitive to chemotherapy.
Fichier principal
Vignette du fichier
PEER_stage2_10.1007%2Fs10549-009-0333-1.pdf (363.97 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-00535339 , version 1 (11-11-2010)

Identifiants

Citer

Marieke E. Straver, Annuska M. Glas, Juliane Hannemann, Jelle Wesseling, Marc J. Vijver, et al.. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Research and Treatment, 2009, 119 (3), pp.551-558. ⟨10.1007/s10549-009-0333-1⟩. ⟨hal-00535339⟩

Collections

PEER
153 Consultations
428 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More